Kinnevik led the $153m Series B funding round in Strand Therapeutics.

Kinnevic, a venture capital firm, led the $153m Series B funding round in Strand Therapeutics, a private biotech company developing programmable mRNA therapies, with participation from Regeneron Ventures, ICONIQ, Amgen Ventures, Alderline Group, JIC-VGI, LG Technology Ventures, Gradiant Corporation, FPV Ventures, Playground Global, Eli Lilly and Company, ANRI, and Potentum. “With support from our investors, we’re advancing our vision of developing safe, effective, and accessible therapies through programmable genetic medicines, especially for those patients with few treatment options,” Jake Becraft, Strand Therapeutics CEO and Co-founder.